X

Trial Profile

A Multicentre, Phase 1B/2 Study of Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naive Advanced or Metastatic Biliary Tract Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Varlitinib (Primary)
Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
Focus Adverse reactions; Therapeutic Use
Sponsors ASLAN Pharmaceuticals

Most Recent Events

22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
12 Jan 2021 Status changed from active, no longer recruiting to discontinued.
18 Nov 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com